Malapposed, uncovered, underexpanded—intravascular imaging lessons on coronary stent thrombosis
Editorial

Malapposed, uncovered, underexpanded—intravascular imaging lessons on coronary stent thrombosis

Nader Mankerious, Jonathon Micha, Sebastian Kufner

Deutsches Herzzentrum München, Technische Universität München, Munich, Germany

Correspondence to: Sebastian Kufner, MD. Deutsches Herzzentrum München, Technische Universität München, Lazarettstrasse 36, 80636 Munich, Germany. Email: kufners@dhm.mhn.de.

Provenance: This is an invited Editorial commissioned by the Section Editor Feng Zhang (Department of Cardiology, Zhongshan Hospital of Fudan University, Shanghai, China).

Comment on: Adriaenssens T, Joner M, Godschalk TC, et al. Optical Coherence Tomography Findings in Patients With Coronary Stent Thrombosis: A Report of the PRESTIGE Consortium (Prevention of Late Stent Thrombosis by an Interdisciplinary Global European Effort). Circulation 2017;136:1007-21.


Submitted Nov 21, 2017. Accepted for publication Dec 04, 2017.

doi: 10.21037/jtd.2017.12.44


Introduction

Three decades after the first stent implantation in a coronary artery, contemporary percutaneous interventional techniques have reached very high levels of efficacy and safety. Successive iterations in stent design—from bare-metal stents (BMS) to first and second-generation drug-eluting stents (DES)—have seen a progressive decline in the rate of stent associated complications. Albeit increasingly rare, stent thrombosis (ST) remains a catastrophic complication associated with severe morbidity and mortality. While overall rates of early and late DES-thrombosis have been halved from 3.0% to 1.5% due to advances in pharmacotherapy and stent design (1-3), in-hospital mortalities of patients suffering from ST still range from 3.6%, for very late ST, to 7.9% for acute and subacute ST (4). As a result, ST has received substantial attention in clinical practice and research.

Beside advances in stent-design and improved pharmacotherapy, pathological studies have advanced our understanding of the mechanisms underlying ST. Human pathology examination has improved the understanding of associations between various morphologic and histologic findings within the stented segment and ST. Nevertheless, the causes of ST are undoubtedly multifactorial and numbers of patients used in these types of analysis are limited. Accordingly, it remains unclear how significant these findings are in “real world” clinical practice. Given the complex interplay between patient and stent-related factors, understanding of the underlying conditions in the stented segment at the time of the ST event remains an important clinical need.

By providing near histology-level images, intravascular optical coherence tomography (OCT) has been used to describe vascular responses following PCI. Subsequently, OCT has been introduced to assess stent coverage and apposition, and detailed characterization of neointimal tissue and vessel wall pathology (5). Therefore, OCT imaging may be the best modality to determine specific underlying mechanisms in real time evaluation of ST events. The number of OCT-imaging studies in the specific setting of ST, however, is limited (6-9). Taking this into consideration, the results of an additional critical appraisal in this field, the report of the PRESTIGE Consortium (Prevention of Late Stent Thrombosis by an Interdisciplinary Global European Effort) in Circulation 2017, should be highlighted (10). Adriaenssens et al. present results from a prospective registry evaluating OCT imaging findings in patients presenting with ST in several centers in Europe.


The current study

The PRESTIGE registry represents the largest available series of patients with OCT imaging during ST presentation, including 231 cases. Patients presented with early-, late- and very late ST. The majority, however, 71.4% of patients presented with late and very late ST, while 28.6% of patients presented with early ST. The underlying stent type was a new generation DES in 50% of cases. The predominant OCT findings were: underexpansion, uncovered stent struts, malapposition, and neoatherosclerosis. The frequency of observations varied according to the timing of ST, accordingly in patients presenting with early, late and very late ST. The rate of stent underexpansion was highest in patients with early (subacute) ST. As expected, uncovered struts were most frequently found in patients with early ST. Although, the proportion of uncovered struts decreased over time, uncovered struts still were reported in every fifth patient presenting with very late ST. Malapposition was a frequent finding in early ST, however was also reported in 14% of patients presenting with very late ST. Neoatherosclerosis was a relatively frequent finding in patients with very late ST, observed in almost one third of patients. The authors summarize: stent underexpansion and uncovered struts were most frequently observed in early ST and neoatherosclerosis was the predominant findings in patients presenting with very late ST.

Before considering potential implications of these findings, some methodological issues should be discussed. First, OCT imaging was performed in the acute setting of ST. Previous studies with deferred imaging strategies had been criticized, as a delay between PCI and intravascular imaging may affect the results (7,11). Nevertheless, a substantial number of patients presenting with ST are in instable clinical condition, additionally it is often impossible to restore blood flow without balloon inflation or even stent implantation, before acquisition of OCT images. In line with these considerations, the proportion of images with residual thrombus burden in this study was high, occurring in more than 95% of cases. Although, only 6% of cases had image quality that precluded further analysis, the high thrombus burden may impact the assessment of the underlying mechanisms of ST, especially in the detection of malapposed and uncovered stent struts.

Second, as the inclusion of patients presenting with hemodynamic instability was not recommended, this subgroup is most likely un-/under-represented in the current analysis.

Finally, the present study did not address the interaction between patient and lesion related factors. Although data on platelet function testing were available in 37% of patients, of which almost three quarters showed high platelet reactivity, data on antiplatelet treatment are only provided for the entire cohort. Therefore, the current study does not provide insights in the specific interaction of platelet reactivity and antiplatelet regime and the association with the etiology of ST in the individual patient.


Uncovered struts, underexpansion, malapposition and neoatherosclerosis

Vascular healing plays a central role in the risk for ST after coronary stent implantation. Autopsy series of patients with ST within BMS identified incomplete or uncovered stent struts as the underlying mechanism in the vast majority of cases (12). In line, endothelial coverage was the strongest histological predictor of late or very late ST within DES in a study by Finn et al. (13). In the PESTO registry (Morphological Parameters Explaining Stent Thrombosis assessed by OCT) uncovered struts (>20%) were frequently observed and accounting for almost 75% of cases of ST with no cause identified (7). Uncovered stent struts were a frequent finding in the PRESTIGE registry, with 33% in patients with late ST and 20% in patients with very late ST. In accordance with previous findings, the proportion of patients with uncovered stent struts was lowest in patients presenting with BMS-ST (7,10). Interestingly, there was no difference in the proportion of uncovered stent struts between patients presenting with ST in first versus second generation DES. This finding is in contradiction to OCT studies supporting a more favorable vascular response and improved neointimal coverage in second—as compared with first-generation DES (14,15).

Stent underexpansion is a well-recognized independent predictor of early ST in both, patients treated with BMS and DES (16,17). Retrospective registries with intravascular ultrasound (IVUS) imaging in patients with BMS-ST, report of stent underexpansion as the cause of early ST in more than every second case (18). Indeed, severe stent underexpansion is more common in subjects with early ST, suggesting that early and late ST have different underlying mechanisms (4,7,19). Underexpansion and acute malapposition occurs as a result of inadequate stent expansion during index PCI. Previous studies report malapposition as the main mechanism in the group of patients presenting with early ST (7,9). In this vein, an autopsy study has shown an association between suboptimal stent implantation in unstable lesions and ST (20), suggesting that improvements of implantation techniques and the reduction of malapposition may lead to a reduction of early ST. Late-acquired malapposition, on the other hand, appears subsequent, as consequence of different mechanisms, including recoil, plaque regression and vessel remodeling mostly observed within DES. In the PRESTIGE registry malapposed struts were reported in 25% of patients presenting with early ST and in 14% of patients presenting with very late ST. These results might reflect the different mechanisms causing malapposition, depending on the timing of diagnosis by OCT.

Thrombotic events related to atherosclerosis and plaque rupture in native coronary arteries is accepted as cause of acute myocardial infarction and sudden death. Consequently, newly formed atherosclerotic changes, within the neointima above a stent, may contribute to thrombosis associated with stents. Although, neoatherosclerosis is observed in both DES and BMS, though there is an ongoing debate on differences in timing and frequency between BMS and DES. Overall, neoatherosclerosis seems to be observed more frequently and earlier in DES as compared with BMS (21). Neoatherosclerosis is associated with ST. Several OCT studies have confirmed that a majority of cases of very late ST in BMS and DES are attributable to neoatherosclerosis (22,23). This is in accordance with the findings of current OCT ST-registries, reporting neoatherosclerosis in up to every third patient presenting with very late ST (7,10). Overall, there is a growing body of evidence implicating that neoatherosclerosis is associated with ST especially in events that occur years after stent implantation. This underlines the importance of new considerations on therapies which target progression of atherosclerosis rather than solely the suppression of neointimal growth after coronary stent implantation. Given the growing number of patients presenting years or even decades after PCI, these concerns, will gain importance.


Clinical perspective

In 1991, one of the first studies reporting outcomes of patients undergoing PCI with placement of a self-expandable BMS reported ST rates as high as 25% (24). Although ST rates declined dramatically over the last decades, when ST occurs it still remains a dramatic iatrogenic event with high mortality (1-3). Nevertheless, there are no current international guidelines to guide treatment (25). This lack of consensus reflects the paucity of evidence in this field. The results of the PRESTIGE Consortium, reported by Adriaenssens et al. (10), further improves our understanding of morphological findings in ST; however, the mechanisms by which morphologic findings interact with patient related factors to cause ST remain open to question. The future diagnostic challenge in ST is to provide accurate assessment of the underlying cause in order to implement appropriate strategies in prevention and therapy in the individual patient. In this vein, intravascular imaging by OCT will play a key role to guide optimal stent implantation in the first instance and to provide further diagnostic insights when ST occurs in the course of time.


Acknowledgements

None


Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.


References

  1. Byrne RA, Joner M, Kastrati A. Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Gruntzig Lecture ESC 2014. Eur Heart J 2015;36:3320-31. [Crossref] [PubMed]
  2. Räber L, Magro M, Stefanini GG, et al. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation 2012;125:1110-21. [Crossref] [PubMed]
  3. Tada T, Byrne RA, Simunovic I, et al. Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients. JACC Cardiovasc Interv 2013;6:1267-74. [Crossref] [PubMed]
  4. Armstrong EJ, Feldman DN, Wang TY, et al. Clinical presentation, management, and outcomes of angiographically documented early, late, and very late stent thrombosis. JACC Cardiovasc Interv 2012;5:131-40. [Crossref] [PubMed]
  5. Prati F, Regar E, Mintz GS, et al. Expert review document on methodology, terminology, and clinical applications of optical coherence tomography: physical principles, methodology of image acquisition, and clinical application for assessment of coronary arteries and atherosclerosis. Eur Heart J 2010;31:401-15. [Crossref] [PubMed]
  6. Prati F, Kodama T, Romagnoli E, et al. Suboptimal stent deployment is associated with subacute stent thrombosis: optical coherence tomography insights from a multicenter matched study. From the CLI Foundation investigators: the CLI-THRO study. Am Heart J 2015;169:249-56. [Crossref] [PubMed]
  7. Souteyrand G, Amabile N, Mangin L, et al. Mechanisms of stent thrombosis analysed by optical coherence tomography: insights from the national PESTO French registry. Eur Heart J 2016;37:1208-16. [Crossref] [PubMed]
  8. Taniwaki M, Radu MD, Zaugg S, et al. Mechanisms of Very Late Drug-Eluting Stent Thrombosis Assessed by Optical Coherence Tomography. Circulation 2016;133:650-60. [Crossref] [PubMed]
  9. Parodi G, La Manna A, Di Vito L, et al. Stent-related defects in patients presenting with stent thrombosis: differences at optical coherence tomography between subacute and late/very late thrombosis in the Mechanism Of Stent Thrombosis (MOST) study. EuroIntervention 2013;9:936-44. [Crossref] [PubMed]
  10. Adriaenssens T, Joner M, Godschalk TC, et al. Optical Coherence Tomography Findings in Patients With Coronary Stent Thrombosis: A Report of the PRESTIGE Consortium (Prevention of Late Stent Thrombosis by an Interdisciplinary Global European Effort). Circulation 2017;136:1007-21. [Crossref] [PubMed]
  11. Mori H, Joner M, Finn AV, et al. Malapposition: is it a major cause of stent thrombosis? Eur Heart J 2016;37:1217-9. [Crossref] [PubMed]
  12. Farb A, Burke AP, Kolodgie FD, et al. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation 2003;108:1701-6. [Crossref] [PubMed]
  13. Finn AV, Joner M, Nakazawa G, et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 2007;115:2435-41. [Crossref] [PubMed]
  14. Kim JS, Jang IK, Kim JS, et al. Optical coherence tomography evaluation of zotarolimus-eluting stents at 9-month follow-up: comparison with sirolimus-eluting stents. Heart 2009;95:1907-12. [Crossref] [PubMed]
  15. Kim JS, Kim JS, Shin DH, et al. Optical coherence tomographic comparison of neointimal coverage between sirolimus- and resolute zotarolimus-eluting stents at 9 months after stent implantation. Int J Cardiovasc Imaging 2012;28:1281-7. [Crossref] [PubMed]
  16. Cheneau E, Leborgne L, Mintz GS, et al. Predictors of subacute stent thrombosis: results of a systematic intravascular ultrasound study. Circulation 2003;108:43-7. [Crossref] [PubMed]
  17. Fujii K, Carlier SG, Mintz GS, et al. Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study. J Am Coll Cardiol 2005;45:995-8. [Crossref] [PubMed]
  18. Uren NG, Schwarzacher SP, Metz JA, et al. Predictors and outcomes of stent thrombosis: an intravascular ultrasound registry. Eur Heart J 2002;23:124-32. [Crossref] [PubMed]
  19. Brodie B, Pokharel Y, Garg A, et al. Predictors of early, late, and very late stent thrombosis after primary percutaneous coronary intervention with bare-metal and drug-eluting stents for ST-segment elevation myocardial infarction. JACC Cardiovasc Interv 2012;5:1043-51. [Crossref] [PubMed]
  20. Nakano M, Yahagi K, Otsuka F, et al. Causes of early stent thrombosis in patients presenting with acute coronary syndrome: an ex vivo human autopsy study. J Am Coll Cardiol 2014;63:2510-20. [Crossref] [PubMed]
  21. Nakazawa G, Otsuka F, Nakano M, et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol 2011;57:1314-22. [Crossref] [PubMed]
  22. Amioka M, Shiode N, Kawase T, et al. Causes of very late stent thrombosis investigated using optical coherence tomography. Intern Med 2014;53:2031-9. [Crossref] [PubMed]
  23. Kang SJ, Lee CW, Song H, et al. OCT analysis in patients with very late stent thrombosis. JACC Cardiovasc Imaging 2013;6:695-703. [Crossref] [PubMed]
  24. Serruys PW, Strauss BH, Beatt KJ, et al. Angiographic follow-up after placement of a self-expanding coronary-artery stent. N Engl J Med 1991;324:13-7. [Crossref] [PubMed]
  25. Alfonso F, Sandoval J. New insights on stent thrombosis: in praise of large nationwide registries for rare cardiovascular events. JACC Cardiovasc Interv 2012;5:141-4. [Crossref] [PubMed]
Cite this article as: Mankerious N, Micha J, Kufner S. Malapposed, uncovered, underexpanded—intravascular imaging lessons on coronary stent thrombosis. J Thorac Dis 2018;10(1):141-144. doi: 10.21037/jtd.2017.12.44

Download Citation